C57BL/6-Bg+/Bg' (beige) T-cell-depleted bone marrow.
Mixing experiments using different numbers of nude bone marrow cells with or without mature thymocytes (unagglutinated by peanut agglutinin) revealed that engraftment of allogeneic T-cell-depleted bone marrow is T-cell dependent. To ensure engraftment, a large inoculum of nude bone marrow must be supplemented with a trace number of donor T cells, whereas a small bone marrow dose from nude donors requires a much larger number of T cells for engraftment. Marked enhancement of donor type chimerism was also found when F1 thymocytes were added to nude bone marrow cells, indicating that the enhancement of bone marrow engraftment by T cells is not only mediated by alloreactivity against residual host cells but may rather be generated by growth factors, the release of which may require specific interactions between T cells and stem cells or between T cells and bone marrow stroma cells.
Graft rejection and leukemia relapse present significant obstacles for transplantation of T-cell-depleted allogeneic bone marrow in leukemia patients (1) . In mice, unlike in man, large numbers of healthy and immunologically vigorous allogeneic chimeras across a complete H-2 barrier have been produced (2, 3) .
One possibility that could explain the differing results in mice and man involves the large bone marrow inoculums traditionally used in mice, usually ranging from 10 x 106 to 30 x 106 cells per mouse [the equivalent of 5-15 x 108 cells per kg (body weight)]. To obtain an equivalent inoculum in man, the bone marrow dose should be even larger, considering that mouse bone marrow is obtained by flushing marrow from the bones, whereas in man bone marrow aspirates are withdrawn from the iliac crest and are highly contaminated with peripheral blood lymphocytes.
Titration of a T-cell-depleted bone marrow (TDBM) dose in the "classical" mouse model [in which animals are conditioned with a single dose of [8] [9] Gy of total body irradiation (TBI)] revealed a range of cell doses in which bone marrow allograft rejection is similar to that found in man (4) . Allogeneic transplants consisting of TDBM cells from C57BL/6 donors were injected into C3H/HeJ recipients who had previously undergone conditioning with 8 Gy of TBI. Chimerism status was defined by testing the H-2 type of spleen cells in each transplanted mouse 1-2 months after transplant. The results revealed that a transplant of 2-4 x 106 cells led to graft rejection in 50-80% of the mice, whereas a transplant of 8 x 106 cells or more resulted in 100% donor type chimerism. This dose-dependent relationship may result from a proportional increase in the total number of transplanted stem cells. Alternatively, it could be mediated by the 0.1-0.5% of T cells left after T-cell depletion.
The question of whether T cells play a critical regulatory role in hematopoiesis has been controversial for more than two decades. A considerable number of studies have demonstrated the possible influence of the thymus (5) (6) (7) (8) or thymus-derived cells (9-13) on hematopoiesis in vivo as well as in vitro (14) (15) (16) (17) .
On the other hand, there are two major arguments against such a role: (i) relatively normal hemnatopoiesis takes place, despite the absence of T-cell function, in human patients and in mice with severe combined immunodeficiency, as well as in athymic nude mice, and (ii) the demonstration that Tcell-depleted mismatched bone marrow can be fully engrafted in lethally irradiated mice. This discrepancy was largely created by quantitative differences in the extent of T-cell depletion and in the total number of bone marrow cells used for transplantation.
In the present study, the relative role of stem cells versus that of T cells in the process that leads to the establishment of durable donor type chimerism was evaluated using C57BL/6-Nu/Nu (nude) mice as bone marrow donors. The use of bone marrow from nude mice, coupled with T-cell depletion, offers a stem-cell source with minimal T-cell contamination, thereby enabling us to study the role ofT cells by reconstituting this highly depleted bone marrow with graduated numbers of purified T cells. Mouse thymocytes were fractionated by differential agglutination with peanut agglutinin (PNA) (18) , and the unaggluAbbreviations: GvHD, graft-versus-host disease; PNA, peanut agglutinin; TDBM, T-cell-depleted bone marrow; TBI, total body irradiation. *To whom reprint requests should be addressed.
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Blood testing was performed 12-14 days after bone marrow transplantation (19) . Chimerism analysis was performed [4] [5] [6] [7] [8] [9] weeks after bone marrow transplantation (19) . To address this critical question more directly, graduated numbers of PNA-mature thymocytes from C57BL/6 mice were added to 8 x 106 TDBM cells from C57BL/6-Nu/Nu mice. To avoid graft-versus-host disease (GvHD), only small numbers of PNA-thymocytes were used in these experiments, but they proved sufficient for promotion of engraftment in that as little as 8 x 104 PNA-thymocytes could greatly enhance donor type chimerism 1-2 months after bone marrow transplantation.
RESULTS
Effect
In three experiments ( Percent of mice engrafted with donor cells represents the fraction ofmice that was found to be either mixed or full donor type chimeras. Staining (%, mean ± SD) of spleen cells from donor type chimeras with anti-H-2b and anti-H-2k antibodies was 65 ± 7 and 9 ± 3, respectively (P < 0.01). Statistical significance of donor type chimerism was established according to the Student's t test. Staining with anti-H-2b of each experimental group was compared to that of the control group (C57BL/6-Nu/Nu bone marrow recipients Proc. Nad. Acad. Sci. USA 87 (1990) mechanisms. One possibility concerns the alloreactivity of donor type T cells, which may eliminate resistance to engraftment mediated by host T cells or stem cells (19) , although GvHD was not observed in graft recipients that survive the initial period after transplant. Alternatively, added donor type T cells may be required in trace amounts as a source of lymphokines, which might be missing during the initial period after transplant.
To reduce the possible effect of the former mechanism, which involves alloreactivity of donor cells against host cells, we chose to use (C3H/HeJ x C57BL/6)F1 PNA-thymocytes. As can be seen in Fig. 1 , these T cells were found to have a marked effect on donor type chimerism as well as on rate of engraftment, when administered together with TDBM cells from C57BL/6-Nu/Nu mice. The relationships among stem-cell dose, number of F1 thymocytes added to the bone marrow, and their combined effect on donor type chimerism were as follows.
When a constant large number (8 x 106) of nude TDBM cells was transplanted with various numbers of F1 thymocytes (ranging from 0.2 x 106 to 4 x 106 cells), the incidence of mice that failed to achieve donor type chimerism after transplantation was reduced from 100lo to 38.5%, resulting in 23% donor type chimera and 38.5% mixed chimera. No GvHD was observed, even when the largest F1 PNAthymocyte inoculum was used. When the number of nude TDBM cells was increased from 2 x 106 to 8 x 106 cells, and a constant number (1 x 106) of F1 PNA-thymocytes was used, the incidence of mice without donor type chimerism was reduced from 100% to 57%, resulting in 29% donor type chimera and 14% mixed chimera. In recipients of 2 x 106 nude TDBM cells plus 1 x 106 F1 PNA-thymocytes, platelet number and hemoglobin levels on day 12 after bone marrow transplantation were 86 ± 47 platelets and 7.6 ± 1.2 g/dl, respectively, whereas in recipients of 8 x 106 nude TDBM cells plus 1 x 106 F1 PNA-thymocytes, they were elevated to 191 ± 129 platelets and 10 ± 2.6 g/dl, respectively.
In leukemia patients, it is possible to obtain only a limited stem cell dose due to the method of bone marrow aspiration, A which is restricted to collection from the iliac crest. At present, therefore, it is more reasonable to attempt to enhance bone marrow engraftment by means other than by an increase in stem-cell dose.
Is it possible to enhance engraftment of low doses of stem cells by increasing the number of T cells in the bone marrow transplant? This question may be answered by using F1 thymocytes void of graft-versus-host activity. In two independent experiments involving a transplant of 2 x 106 TDBM cells from C57BL/6 donors, engraftment was markedly enhanced by adding large numbers of F1 PNA-thymocytes to the bone marrow inoculum. In one experiment (Table 3) , 38% (5 of 13 mice) donor type chimerism resulted from an inoculum to which T cells had not been added. When 8 x 106 F1 PNA-thymocytes were added to the inoculum, donor type chimerism was enhanced to 89% (16 of 18 mice). In the second experiment (detailed data not shown), the addition of 4 x 106 F1 PNA-thymocytes to the bone marrow inoculum enhanced donor type chimerism from 25% to 59%. Thus, when a relatively low number of stem cells is used, the number of T cells required to guarantee durable engraftment seems to be larger than the bone marrow inoculum.
Interestingly, transplanted mice were primarily of host type or donor type. Mixed chimera were rare (1 of 13 mice in the control group and 1 of 18 mice among the recipients of F1 thymocytes), ruling out the possibility that enhancement by It would seem that a significant improvement in clinical transplantation requires either a significant increase in stem cell number or a much larger dose of T cells than is currently employed, an option that is limited due to GvHD. Our data with F1 thymocytes suggest that enhancement of engraftment can be achieved by T cells void of graft-versus-host activity. It is, therefore, possible that a T-cell subpopulation incapable of producing GvHD may enhance engraftment of bone marrow allografts. However, these activities may be inseparable.
It could be argued that the enhancement of engraftment of nude bone marrow cells might be mediated by pluripotent stem cells present in the PNA-F1 thymocyte preparation.
However, this possibility is unlikely, as such F1 stem cells would give rise to progenies that would be stained by both anti-H-2b and anti-H-2k antibodies and, therefore, could not account for the marked reduction in host type cells found in our assay.
Still, it is possible that some cell types of the thymic environment other than T lymphocytes could be responsible in part for the effect. Preliminary cell-sorting experiments with specific T-cell markers (data not shown) further support the suggestion that the enhancement ofdonor type chimerism is mediated by F1 PNA-thymocytes.
Augmentation of bone marrow engraftment by thymocytes has been demonstrated in various murine models of bone marrow transplantation. Goodman and Shinpock (9, 10) have shown that donor type thymocytes can somewhat abrogate hybrid resistance and enhance hematopoiesis in fully irradiated F1 recipients of parental bone marrow. Although interpretation of these studies was difficult, due to the occurrence of GvHD-induced splenomegaly, it was established that the addition of donor type thymocytes in large numbers resulted in an increase in iron incorporation as well as in circulating erythrocytes.
This augmentative effect was also seen in allogeneic and xenogeneic chimeras (20) . Again, morbidity was also increased due to an enhanced incidence of GvHD. However, Goodman and Shinpock (21) found that in the few mice surviving GvHD, donor type erythrocytes persisted for extended periods of time. Whether this enhancement is mediated by donor anti-host responses or by non-GvHD-producing T cells could not be determined by these studies.
In line with these data, Zipori and Trainin (7) demonstrated that bone marrow cells from both neonatally thymectomized or athymic nude mice manifested a reduced radioprotective capacity when inoculated into lethally irradiated syngeneic recipients. Zipori and Trainin (7) suggested that this was due to a lower rate of proliferation among hematopoietic cells originating in the bone marrow of thymectomized mice. Implantation with intact thymic tissue reversed the reduction of colony forming units associated with thymectomy, whereas injection of thymocytes was not followed by any noticeable change. The discrepancy between the study of Zipori and Trainin (7) and other in vivo studies (9) (10) (11) (12) (13) regarding the effect of thymocytes has not been explained but may be associated with the type of bone marrow recipient (e.g., syngeneic in the former versus semiallogeneic or allogeneic in the latter) used in each study.
Other evidence for the role of T cells in hematopoiesis was demonstrated by Sharkis et al. (12, 13) Our experiments that made use of nude mice as a source of allogeneic TDBM cells, and PNA-thymocytes as a source of purified mature T cells, enabled us to demonstrate the regulatory role of T cells in allogeneic recipients after conditioning similar to that used in the treatment of leukemia patients. This role could not be detected in our studies in which a high dose (8 x 106 cells) of normal T-cell-depleted C57BL/6 bone marrow cells was used as a source of stem cells, and it seems likely, therefore, that it was also overlooked in several murine models that made use of doses of TDBM cells equal to or greater than 1 x 107 in recipients irradiated with more than 8 Gy of TBI. When the stem-cell dose is relatively large, a trace amount of T cells is required, whereas, with a relatively low number of stem cells, a very large number of T cells may be needed to ensure donor type chimerism (Table 3) . Thus, the controversy regarding the role of T cells in donor type engraftment may be attributed to quantitative differences.
In line with our findings, it may be possible to interpret two intriguing clinical reports. Martin et al. (23) described extremely poor results when using TDBM cells for transplantation in leukemia patients. They took extra care to drastically purge T cells from their bone marrow preparations, and it is possible that this led to the higher rate (over 50%) of graft rejection experienced in their series compared to what is commonly found in other centers using less-extensive T-cell depletion. At the other extreme, Bacigalupo et al. (24) reported the results of clinical trials involving partial T-cell depletion that made use of a mouse monoclonal antibody (anti-BT5/9, specific for 15% of peripheral blood T cells and 5-10% of bone marrow T cells; CD not yet defined) (25) to eliminate only a small subset of inducer/helper T cells. Surprisingly, the incidence of graft failure and leukemia relapse was significantly higher among these patients than among those treated at other centers with conventional T-cell depletion techniques that used pan-T-cell antibodies. These results would suggest either that treatment with this antibody was especially toxic to pluripotent bone marrow stem cells or that BT5/9' T cells may play an important regulatory role in bone marrow engraftment. Bacigalupo et al. (24) support the latter possibility, as removal of BT5/9' T cells does not affect the growth of myeloid or erythroid colonies in vitro.
Our long-term assay for durable hematopoietic engraftment, which uses add-back experiments mixing purified thymocytes with TDBM cells from nude donors, should enable isolation of such hypothetical T-cell subpopulations. It should permit the investigation of whether the role of T cells shown in our model is mediated or could be replaced by lymphokines. Since F1 T cells are not present in larger animals or in man, the study of the latter possibility holds greater potential for refining bone marrow transplantation procedures in leukemia patients.
